Nanoparticles as delivery carriers for anticancer prodrugs

Bibliography

• Albert A. Chemical aspects of selective toxicity. Nature 1958;182:421-2
   PubMed Web of Science ®Google Scholar
• Sloan KB, Wasdo S. Designing for topical delivery: prodrugs can make the difference. Med Res Rev 2003;23:763-93
   PubMed Web of Science ®Google Scholar
• Stella VJ. Prodrugs: some thoughts and current issues. J Pharm Sci 2010;99:4755-65
   PubMed Web of Science ®Google Scholar
• Hsieh PW, Hung CF, Fang JY. Current prodrug design for drug discovery. Curr Pharm Des 2009;15:2236-50
   PubMed Web of Science ®Google Scholar
• Ettmayer P, Amidon GL, Clement B, Lessons learned from marketed and investigational prodrugs. J Med Chem 2004;47:2393-404
   PubMed Web of Science ®Google Scholar
• Rautio J, Kumpulainen H, Heimbach T, Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008;7:255-70
   PubMed Web of Science ®Google Scholar
• Huttunen KM, Raunio H, Rautio J. Prodrugs–from serendipity to rational design. Pharmacol Rev 2011;63:750-71
   PubMed Web of Science ®Google Scholar
• Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 2008;13:248-60
   PubMed Web of Science ®Google Scholar
• Trivedi RR, Kompella UB. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine 2010;5:485-505
   PubMed Web of Science ®Google Scholar
• Fang JY, Lee WR, Shen SC, Effect of liposome encapsulation of tea catechins on their accumulation in basal cell carcinomas. J Dermatol Sci 2006;42:101-9
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther 2006;8:39-45
   PubMed Web of Science ®Google Scholar
• Zhigaltsev IV, Winters G, Srinivasulu M, Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release 2010;144:332-40
   PubMed Web of Science ®Google Scholar
• Akagi T, Baba M, Akashi M. Preparation of nanoparticles by the self-organization of polymers consisting of hydrophobic and hydrophilic segments: potential applications. Polymer 2007;48:6729-47
   Web of Science ®Google Scholar
• Croyand SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des 2006;12:4669-84
   PubMed Web of Science ®Google Scholar
• Baspinar Y, Keck CM, Borchert HH. Development of a positively charged prednicarbate nanoemulsion. Int J Pharm 2010;383:201-8
   PubMed Web of Science ®Google Scholar
• Wen CJ, Yen TC, Al-Suwayeh SA, In vivo real-time fluorescence visualization and brain-targeting mechanisms of lipid nanocarriers with different fatty ester:oil ratios. Nanomedicine 2011;6:1545-59
   PubMed Web of Science ®Google Scholar
• Beduneau A, Hindre F, Clavreul A, Brain targeting using novel lipid nanovectors. J Control Release 2008;126:44-9
   PubMed Web of Science ®Google Scholar
• Jin Y, Xin R, Ai P, Self-assembled drug delivery systems. 2. Cholesteryl derivatives of antiviral nucleotide analogues: synthesis, properties and the vesicle formation. Int J Pharm 2008;350:330-7
   PubMedGoogle Scholar
• Sagnella SM, Gong X, Moghaddam MJ, Nanostructured nanoparticles of self-assembled lipid pro-drugs as a route to improved chemotherapeutic agents. Nanoscale 2011;3:919-24
   PubMed Web of Science ®Google Scholar
• Onishi H, Machida Y. In vitro and in vivo evaluation of microparticulate drug delivery systems composed of macromolecular prodrugs. Molecules 2008;13:2136-55
   PubMed Web of Science ®Google Scholar
• Elsadek B, Graeser R, Esser N, Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study. Eur J Cancer 2010;46:3434-44
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006;58:1532-55
   PubMed Web of Science ®Google Scholar
• Rooseboom M, Commandeur JNM, Vermeulen NPE. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 2004;56:53-102
   PubMed Web of Science ®Google Scholar
• Kaur IP, Bhandari R, Bhandari S, Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008;127:97-109
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV. New technologies for drug delivery across the blood brain barrier. Curr Pharm Des 2004;10:1355-63
   PubMed Web of Science ®Google Scholar
• Brioschi A, Zenga F, Zara GP, Solid lipid nanoparticles: could they help to improve the efficacy of pharmacological treatments for brain tumors? Neurol Res 2007;29:324-30
   PubMed Web of Science ®Google Scholar
• Bhalla KN, Kumar GN, Walle K, Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 1999;5:1723-30
   PubMed Web of Science ®Google Scholar
• Forrest ML, Yanez JA, Remsberg CM, Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm Res 2008;25:194-206
   PubMed Web of Science ®Google Scholar
• Shan L, Cui S, Du C, A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy. Biomaterials 2012;33:146-62
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Hurria A, Cirrincione CT, Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 2012;23:632-8
   PubMed Web of Science ®Google Scholar
• Wang Y, Xin D, Liu K, Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjug Chem 2009;20:2214-21
   PubMed Web of Science ®Google Scholar
• Xin D, Wang Y, Xiang J. The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: synthesis, self-assembled property, drug release, and in vitro efficiency. Pharm Res 2010;27:380-9
   PubMed Web of Science ®Google Scholar
• Li G, Liu J, Pang Y, Polymeric micelles with water-insoluble drug as hydrophobic moiety for drug delivery. Biomacromolecules 2011;12:2016-26
   PubMed Web of Science ®Google Scholar
• Stella B, Arpicco S, Rocco F, Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int J Pharm 2007;344:71-7
   PubMed Web of Science ®Google Scholar
• Gong X, Moghaddam MJ, Sagnella SM, Lyotropic liquid crystalline self-assembly material behavior and nanoparticulate dispersions of a phytanyl pro-drug analogue of capecitabine−A chemotherapy agent. ACS Appl Mater Interfaces 2011;3:1552-61
   PubMed Web of Science ®Google Scholar
• Gong X, Moghaddam MJ, Sagnella SM, Lamellar crystalline self-assembly behaviour and solid lipid nanoparticles of a palmityl prodrug analogue of capecitabine−A chemotherapy agent. Colloids Surf B Biointersurf 2011;85:349-59
   PubMed Web of Science ®Google Scholar
• Zhang G, Liu T, Chen YH, Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo. Clin Cancer Res 2009;15:201-7
   PubMed Web of Science ®Google Scholar
• Vine KL, Locke JM, Bremner JB, Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro. Bioorg Med Chem Lett 2010;20:2908-11
   PubMed Web of Science ®Google Scholar
• Crosasso P, Brusa P, Dosio F, Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. J Pharm Sci 1997;86:832-9
   PubMed Web of Science ®Google Scholar
• McCarron PA, Hall M. Incorporation of novel 1-alkylcarbonyloxymethyl prodrugs of 5-fluorouracil into poly(lactide-co-glycolide) nanoparticles. Int J Pharm 2008;348:115-24
   PubMed Web of Science ®Google Scholar
• Immordino ML, Brusa P, Rocco F, Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release 2004;100:331-46
   PubMed Web of Science ®Google Scholar
• Couvreur P, Stella B, Reddy LH, Squalenoyl nanomedicines as potential therapeutics. Nano Lett 2006;6:2544-8
   PubMed Web of Science ®Google Scholar
• Bildstein L, Marsaud V, Chacun H, Extracellular-protein-enhanced cellular uptake of squalenoyl gemcitabine from nanoassemblies. Soft Matter 2010;6:5570-80
   Web of Science ®Google Scholar
• Bildstein L, Pili B, Marsaud V, Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. Eur J Pharm Biopharm 2011;79:612-20
   PubMed Web of Science ®Google Scholar
• Arias JL, Reddy LH, Couvreur P. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting. Langmuir 2008;24:7512-19
   PubMed Web of Science ®Google Scholar
• Ansell SM, Johnstone SA, Tardi PG, Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. J Med Chem 2008;51:3288-96
   PubMed Web of Science ®Google Scholar
• Schluep T, Gunawan P, Ma L, Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin Cancer Res 2009;15:181-9
   PubMed Web of Science ®Google Scholar
• Schluep T, Hwang J, Cheng J, Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 2006;12:1606-14
   PubMed Web of Science ®Google Scholar
• Taneja D, Namdeo A, Mishra PR, High-entrapment liposomes for 6-mercaptopurine−A prodrug approach. Drug Dev Ind Pharm 2000;23:1315-19
   Google Scholar
• Kouides PA, Bennett JM. Morphology and classification of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992;6:485-99
   PubMed Web of Science ®Google Scholar
• Raza A, Galili N, Callander N, Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol 2009;2:20
   PubMedGoogle Scholar
• Bildstein L, Dubernet C, Marsaud V, Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. J Control Release 2010;147:163-70
   PubMed Web of Science ®Google Scholar
• Arias JL, Reddy LH, Othman M, Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. ACS Nano 2011;5:1513-21
   PubMed Web of Science ®Google Scholar
• Shubayev VI, Pisanic TR, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 2009;61:467-77
   PubMed Web of Science ®Google Scholar
• Bildstein L, Hillaireau H, Desmaele D, Freeze-drying of squalenoylated nucleoside analogue nanoparticles. Int J Pharm 2009;381:140-5
   PubMed Web of Science ®Google Scholar
• Caron J, Reddy LH, Lepetre-Mouelhi S, Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues. Bioorg Med Chem Lett 2010;20:2761-4
   PubMed Web of Science ®Google Scholar
• Lundberg BB. Preparation and characterization of polymeric pH-sensitive STEALTH® nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel. Int J Pharm 2011;408:208-12
   PubMed Web of Science ®Google Scholar
• Murad F. Discovery of some of the biological effects of nitric oxide ad its role in cell signaling. Angew Chem Int Ed 1999;38:1856-68
   Google Scholar
• Kumar V, Hong SY, Maciag AE, Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and double JS-K, through incorporation into PEG-protected nanoparticles. Mol Pharm 2010;7:291-8
   PubMed Web of Science ®Google Scholar
• Vij N, Min T, Marasigan R, Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J Nanobiotechnol 2010;8:22
   PubMedGoogle Scholar
• Cheon EP, Hong JH, Han HK. Enhanced cellular uptake of Ara-C via a peptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells. J Pharm Pharmacol 2006;58:927-32
   PubMed Web of Science ®Google Scholar
• Tokunaga Y, Iwasa T, Fujisaki J, Liposomal sustained-release delivery systems for intravenous injection. IV. Antitumor activity of newly synthesized lipophilic 1-beta-D-arabinofuranosylcytosine prodrug-bearing liposomes. Chem Pharm Bull 1988;36:3574-83
   PubMed Web of Science ®Google Scholar
• Mori A, Kennel SJ, Huang L. Immunotargeting of liposomes containing lipophilic antitumor prodrugs. Pharm Res 1993;10:507-14
   PubMed Web of Science ®Google Scholar
• Dimou A, Syrigos KN, Saif MW. Is there a role for mitomycin C in metastatic colorectal cancer? Expert Opin Invest Drugs 2010;19:723-35
   PubMed Web of Science ®Google Scholar
• Gabizon AA, Tzemach D, Horowitz AT, Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in Pegylated liposomes. Clin Cancer Res 2006;12:1913-20
   PubMed Web of Science ®Google Scholar
• Dhar S, Daniel W, Giljohann DA, Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J Am Chem Soc 2009;131:14652-3
   PubMed Web of Science ®Google Scholar
• Seferos DS, Prigodich AE, Giljohann DA, Polyvalent DNA nanoparticle conjugates stabilize nucleic acids. Nano Lett 2009;9:308-11
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Dhar S, Gu FX, Langer R, Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci 2008;105:17356-61
   PubMed Web of Science ®Google Scholar
• Dhar S, Kolishetti N, Lippard SJ, Targeted delivery of a cisplatin prodrug for safer and more effective cancer therapy in vivo. Proc Natl Acad Sci 2011;108:1850-5
   PubMed Web of Science ®Google Scholar
• Kholishetti N, Dhar S, Valencia PM, Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci 2010;107:17939-44
   PubMed Web of Science ®Google Scholar
• Vaughan EE, Geiger RC, Miller AM, Microtubule acetylation through HDAC6 inhibition results in increased transfection efficiency. Mol Ther 2008;16:1841-7
   PubMed Web of Science ®Google Scholar
• Ishii Y, Hattori Y, Yamada T, Histone deacetylase inhibitor prodrugs in nanoparticle vector enhanced gene expression in human cancer cells. Eur J Med Chem 2009;44:4603-10
   PubMed Web of Science ®Google Scholar
• Versluis AJ, Rump ET, Rensen PCN, Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo. J Pharmacol Exp Ther 1999;289:1-7
   PubMed Web of Science ®Google Scholar
• Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992;19:670-86
   PubMed Web of Science ®Google Scholar
• Yu BT, Sun X, Zhang ZR. Enhanced liver targeting by synthesis of N1-stearyl-5-Fu and incorporation into solid lipid nanoparticles. Arch Pharm Res 2003;26:1096-101
   Google Scholar
• Holland EC. Glioblastoma multiform: the terminator. Proc Natl Acad Sci 2000;97:6242-4
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Gibbs AR, Hunt CA, Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release 2007;124:163-71
   PubMed Web of Science ®Google Scholar
• Rensen PC, de Vrueh RL, Kuiper J, Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 2001;47:251-76
   PubMed Web of Science ®Google Scholar
• Tang H, Murphy CJ, Zhang B, Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects. Nanomedicine 2010;5:855-65
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang G, Chen YH, Tissue specific expression of suicide genes delivered by nanoparticles inhibits gastric carcinoma growth. Cancer Biol Ther 2006;5:1683-90
   PubMed Web of Science ®Google Scholar
• Christiansen K, Bjerring P, Troilius A. 5-ALA for photodynamic photo-rejuvenation-Optimization of treatment regime based on normal-skin fluorescence measurements. Lasers Surg Med 2007;39:302-10
   PubMed Web of Science ®Google Scholar
• Zhang LW, Al-Suwayeh SA, Hung CF, Oil components modulate the skin delivery of 5-aminolevulinic acid and its ester prodrug from oil-in-water and water-in-oil nanoemulsions. Int J Nanomed 2011;6:693-704
   PubMed Web of Science ®Google Scholar
• Yang RSH, Chang LW, Yang CS, Pharmacokinetics and physiologically-based pharmacokinetic modeling of nanoparticles. J Nanosci Nanotechnol 2010;10:8482-90
   PubMed Web of Science ®Google Scholar
• Oberdorster G, Stone V, Donaldson K. Toxicology of nanoparticles: a historical perspective. Nanotoxicology 2007;1:2-25
   Web of Science ®Google Scholar